Lọc theo
New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Lebrikizumab and dupilumab appear to be equally efficacious when used in the short-term treatment of atopic dermatitis in adults, according to the results of a network meta-analysis.
In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.
The use of oral corticosteroids for more than 90 days among individuals with atopic dermatitis (AD) appears to be associated with a slight increase in the risk of adverse events (AEs), according to a study.
The IL-13 inhibitor cendakimab appears to be beneficial in the treatment of atopic dermatitis (AD), with the results of a phase II study showing that a dosing schedule of 720 mg once weekly helps reduce the severity of the said condition.
Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024
The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.
Treatment with oral roflumilast results in reduced body weight and appetite after 24 weeks in patients with psoriasis, a study has shown.
Nearly half of patients with classic dermatomyositis (DM) develop into postmyopathic (PM)DM, according to a study. Many of them continue to suffer from muscle disease or have moderate or severe skin disease.
A retrospective review of medical records show that paediatric patients with alopecia areata (AA) in Singapore respond well to currently available treatments.
